140 related articles for article (PubMed ID: 9570425)
1. Potential cardioprotective effect of mibefradil in the long-term treatment of hypertension.
Waeber B
Cardiology; 1998; 89 Suppl 1():16-22. PubMed ID: 9570425
[TBL] [Abstract][Full Text] [Related]
2. Mibefradil: a new class of calcium-channel antagonists.
Billups SJ; Carter BL
Ann Pharmacother; 1998 Jun; 32(6):659-71. PubMed ID: 9640486
[TBL] [Abstract][Full Text] [Related]
3. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
Brogden RN; Markham A
Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
[TBL] [Abstract][Full Text] [Related]
4. Differential properties of mibefradil in hypertension and angina.
Kobrin I
J Hypertens Suppl; 1997 Dec; 15(5):S33-40. PubMed ID: 9481614
[TBL] [Abstract][Full Text] [Related]
5. The relevance of T-type calcium antagonists: a profile of mibefradil.
Glasser SP
J Clin Pharmacol; 1998 Aug; 38(8):659-69. PubMed ID: 9725540
[TBL] [Abstract][Full Text] [Related]
6. Mibefradil: a selective T-type calcium antagonist.
Massie BM
Am J Cardiol; 1997 Nov; 80(9A):23I-32I. PubMed ID: 9375939
[TBL] [Abstract][Full Text] [Related]
7. Steady-state trough plasma mibefradil concentrations and correlation to blood pressure response in hypertensive patients with chronic renal disease.
Pordy R; Woittiez A
Int J Clin Pharmacol Res; 1998; 18(3):105-8. PubMed ID: 9825266
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Noll G; Lüscher TF
Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
[TBL] [Abstract][Full Text] [Related]
10. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
[TBL] [Abstract][Full Text] [Related]
11. Mibefradil, a pharmacologically distinct calcium antagonist.
Ernst ME; Kelly MW
Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
[TBL] [Abstract][Full Text] [Related]
12. Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
Oparil S
Am J Hypertens; 1998 Apr; 11(4 Pt 3):88S-94S. PubMed ID: 9607372
[TBL] [Abstract][Full Text] [Related]
13. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist.
Triggle DJ
Am J Cardiol; 1996 Nov; 78(9A):7-12. PubMed ID: 8903279
[TBL] [Abstract][Full Text] [Related]
15. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
[TBL] [Abstract][Full Text] [Related]
16. Use of calcium channel blockers in hypertension.
Conlin PR; Williams GH
Adv Intern Med; 1998; 43():533-62. PubMed ID: 9506192
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
[TBL] [Abstract][Full Text] [Related]
18. Mibefradil, a selective calcium T-channel blocker, in stroke-prone spontaneously hypertensive rats.
Vacher E; Richer C; Fornes P; Clozel JP; Giudicelli
J Cardiovasc Pharmacol; 1996 May; 27(5):686-94. PubMed ID: 8859939
[TBL] [Abstract][Full Text] [Related]
19. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency.
Welker HA; Weidekamm E; Houwing N; de Chatel R
Pharmacology; 1998 Jun; 56(6):297-307. PubMed ID: 9654216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
